Berry Wealth Group LP Has $3.12 Million Stock Holdings in AbbVie Inc. $ABBV

AbbVie reported Q3 results showing EPS of $1.86 versus $1.77 expected and revenue of $15.78B vs $15.58B, with quarterly revenue up 9.1% year-over-year; management set Q4 2025 EPS guidance at $3.320–3.360. The company raised its quarterly dividend to $1.73 ($6.92 annualized, 3.1% yield) while institutional ownership sits at ~70.2% and Berry Wealth Group notably increased its ABBV stake to 16,804 shares (worth ~$3.12M). Analysts have recently boosted price targets and ratings (consensus target $241.85), though valuation metrics (market cap ~$400.7B, P/E ~108) and an elevated payout ratio (524%) warrant scrutiny for leverage and sustainability.

Analysis

Market structure: Institutional buying (AbbVie ~70% owned by institutions) and multiple analyst target upgrades support near-term demand; consensus target $241.85 vs spot $226.72 implies ~6.7% upside but technicals show limited slack (50‑day $227.7, 200‑day $206.7). Direct winners are large-cap immunology/oncology franchises (ABBV, peers with strong branded franchises) while small biotechs without commercial scale are disadvantaged as capital flows concentrate. Cross-asset: ABBV’s low beta (0.5) and large market cap reduce equity‑risk transmission, but widening credit spreads or a sector regulatory shock would compress equity and credit simultaneously.

Risk assessment: Key tail risks are regulatory/safety rulings (Rinvoq class safety headlines), accelerated Humira biosimilar share losses, and balance‑sheet stress given reported payout ratio 524% and debt/equity 44.14 — dividend continuity depends on FCF, not EPS. Time horizons: near term (days–weeks) technical pullback to the 200‑day MA (~$206) is plausible; medium term (3–12 months) depends on quarterly beats/guidance and pipeline uptake; long term (1–3 years) hinges on Rinvoq/Skyrizi adoption replacing Humira revenue. Catalysts: upcoming quarterly prints, patent litigation outcomes, and any FDA safety communications.

Trade implications: If constructive, establish a 2–3% long ABBV equity position sized to portfolio risk with target $260 in 9–12 months and hard stop at $192 (~15% below spot). Preferred option play: buy 12‑month 230/280 call spread (debit) to cap capital while keeping upside to $280; alternative income entry: sell 3‑month 240 covered calls to harvest premium while collecting $6.92 annual dividend. Pair trade: long ABBV / short PFE (or large diversified pharma) 1:1 to express premium on branded growth vs commoditizing legacy drugs.

Contrarian view: The market may both underprice branded product growth and overprice dividend sustainability — AbbVie can re-rate if Rinvoq/Skyrizi deliver >10% organic growth, but dividend risk is real if FCF falls below dividend cash needs. Historical parallel: post‑Humira transition re‑ratings occurred when new products offset decline; watch FCF-to-dividend ratio over next four quarters — a sustained ratio >1.2 would validate upside thesis, while <0.9 should trigger de‑risking. Unintended consequence: aggressive buybacks to prop EPS could increase leverage and amplify downside in a mid‑cycle slowdown.

Key Decisions for Investors

• Establish a 2–3% long position in ABBV (NYSE:ABBV) using equity or buy the 12‑month 230/280 call spread sized to equal 2% notional exposure; target $260 within 9–12 months, place stop-loss at $192 (≈15% below entry).
• If collecting yield, buy ABBV and sell 3‑month covered calls at the 240 strike (roll monthly); this increases yield and caps upside near analyst consensus while collecting the $6.92 annualized dividend.
• Implement a relative‑value pair: long ABBV / short PFE equal dollar notional for 6–12 months to capture branded‑growth premium; reduce pair if ABBV/PFE spread narrows by >20% or if ABBV misses guidance.
• Use cash‑secured 12‑month 200 puts to acquire ABBV at a ~12% discount to spot (premium adjusted entry) only if willing to own stock and when implied vol > historical 12‑month average; close if assigned and FCF-to-dividend ratio falls below 0.9.